CDK4/6 Inhibitors-based Combinational Therapy for Human Cancers by ZHANG Baihong, YUE Hongyun

Subjects: Get full text

Efficacy of Palbociclib and Endocrine Treatment in Heavily Pretreated Hormone Receptor-positive/HER2-negative Advanced Breast Cancer: Retrospective Multicenter Trial by Atakan Demir, Nil Molinas Mandel, Semra Paydas, Gökhan Demir, Özlem Er, Nazım Serdal Turhal, Sevil Bavbek, Yeşim Eralp, Pınar Mualla Saip, Emine Nilüfer Güler, Adnan Aydıner, Başak Oyan Uluç, Sadettin Kılıçkap, Necdet Üskent, Nuri Karadurmuş, Mehmet Ali Kaplan, Mustafa Teoman Yanmaz, Hacer Demir, Özkan Alan, Taner Korkmaz, Polat Olgun, Özlem Sönmez Uysal, Kadri Altundağ, Şeyda Gündüz, Meral Günaldı, Murat Sarı, İsmail Beypınar, Gül Başaran

Subjects: Get full text

Mechanisms of Resistance to CDK4/6 Inhibitors and Predictive Biomarkers of Response in HR+/HER2-Metastatic Breast Cancer—A Review of the Literature by Ioana-Miruna Stanciu, Andreea Ioana Parosanu, Cristina Orlov-Slavu, Ion Cristian Iaciu, Ana Maria Popa, Cristina Mihaela Olaru, Cristina Florina Pirlog, Radu Constantin Vrabie, Cornelia Nitipir

Subjects: “…CDK4/6 inhibitors…”
Get full text

CDK 4/6 inhibitors combined with radiotherapy: A review of literature by Claire Bosacki, Wafa Bouleftour, Sandrine Sotton, Alexis Vallard, Elisabeth Daguenet, Hamza Ouaz, Iohel Cojoracu, Dariush Moslemi, Mona Molekzadehmoghani, Nicolas Magné

Subjects: Get full text

The prognostic role of variations in tumour markers (CEA, CA15.3) in patients with metastatic breast cancer treated with CDK4/6 inhibitors by Federico Sottotetti, Elisa Ferraris, Barbara Tagliaferri, Raffaella Palumbo, Erica Quaquarini, Cristina Teragni, Emanuela Balletti, Claudia Leli, Andrea Premoli, Ludovica Mollica, Silvia Puglisi, Silvia Sardi, Alberto Malovini, Paolo Pedrazzoli, Antonio Bernardo

Subjects: Get full text

Clinico-Immunological Effects of a Single-Agent CDK4/6 Inhibitor in Advanced HR+/HER2− Breast Cancer Based on a Window of Opportunity Study by Alberto D’Angelo, Fabiola Giudici, Robert Chapman, Jacob Darlow, Huseyin Kilili, Navid Sobhani, Mattia Cinelli, Maria Rosa Cappelletti, Carla Strina, Manuela Milani, Daniele Generali

Subjects: Get full text

Ribociclib in the Treatment of Hormone-Receptor Positive/HER2-Negative Advanced and Early Breast Cancer: Overview of Clinical Data and Patients Selection by Parati MC, Pedersini R, Perego G, Reduzzi R, Savio T, Cabiddu M, Borgonovo K, Ghilardi M, Luciani A, Petrelli F

Subjects: Get full text

Recent Progress in CDK4/6 Inhibitors and PROTACs by Hao Wang, Jianfei Ba, Yue Kang, Zeqiao Gong, Tingting Liang, Yahong Zhang, Jianguo Qi, Jianhong Wang

Subjects: Get full text

CDK4/6 inhibitors in advanced breast cancer, what is beyond? by Amrallah A. Mohammed, Hanaa Rashied, Fifi Mostafa Elsayed

Subjects: Get full text

SARS-CoV-2 neutralizing antibodies after first vaccination dose in breast cancer patients receiving CDK4/6 inhibitors by Flora Zagouri, Evangelos Terpos, Oraianthi Fiste, Michalis Liontos, Alexandros Briasoulis, Ioanna Katsiana, Efi Skafida, Christos Markellos, Elena Kunadis, Angeliki Andrikopoulou, Maria Kaparelou, Konstantinos Koutsoukos, Maria Gavriatopoulou, Efstathios Kastritis, Ioannis P. Trougakos, Meletios-Athanasios Dimopoulos

Subjects: Get full text

Research Progress of CDK4/6 Inhibitors in Non-small Cell Lung Cancer by Qiong QIN, Yaoyao REN, Diansheng ZHONG

Subjects: Get full text

Activity of CDK4/6 inhibitors and parameters affecting survival in elderly patients in age-subgroups: Turkish Oncology Group (TOG) retrospective study by Seda Kahraman, Mutlu Hizal, Burcin Cakan Demirel, Deniz Can Guven, Ozge Gumusay, Basak Oyan Uluc, Ertugrul Bayram, Burcu Gulbagci, Alper Yasar, Sena Ece Davarci, Eda Eylemer Mocan, Omer Acar, Deniz Isik, Esra Aydin, Yusuf Karakas, Melike Ozcelik, Murat Keser, Sadi Kerem Okutur, Onder Eren, Serkan Menekse, Dincer Aydin, Funda Yilmaz, Ozlem Dogan, Gulhan Ozkanli, Hakan Yucel, Veli Sunar, Musa Baris Aykan, Ozlem Ozdemir, Berna Bozkurt Duman, Merve Keskinkilic, Teoman Sakalar, Ali Inal, Muge Karaoglanoglu, Asude Aksoy, Muhammed Muhiddin Er, Nazim Serdar Turhal, Nurhan Onal Kalkan, Mehmet Ali Nahit Sendur

Subjects: “…CDK 4/6 inhibitors…”
Get full text

CDK4/6 inhibitors: A potential therapeutic approach for triple negative breast cancer by Lubaid Saleh, Caroline Wilson, Ingunn Holen

Subjects: “…CDK/4/6 inhibitors…”
Get full text

CDK4/6 Inhibitors and Arthralgia: A Single Institution Experience by Angeliki Andrikopoulou, Oraianthi Fiste, Kleoniki Apostolidou, Efthymia Skafida, Christos Markellos, Michalis Liontos, Anastasios Kyriazoglou, Meletios-Athanasios Dimopoulos, Flora Zagouri

Subjects: “…CDK4/6 inhibitors…”
Get full text

Adverse Cardiovascular Events Associated With Cyclin‐Dependent Kinase 4/6 Inhibitors in Patients With Metastatic Breast Cancer by Michael G. Fradley, Nam H. K. Nguyen, David Madnick, Yiqing Chen, Angela DeMichele, Igor Makhlin, Susan Dent, Benedicte Lefebvre, Joseph Carver, Jenica N. Upshaw, David DeRemer, Bonnie Ky, Avirup Guha, Yan Gong

Subjects: Get full text

Ki67 and PR in Patients Treated with CDK4/6 Inhibitors: A Real-World Experience by Michela Palleschi, Roberta Maltoni, Sara Ravaioli, Alessandro Vagheggini, Francesca Mannozzi, Francesca Fanini, Francesca Pirini, Maria Maddalena Tumedei, Eleonora Barzotti, Lorenzo Cecconetto, Samanta Sarti, Silvia Manunta, Paola Possanzini, Anna Fedeli, Annalisa Curcio, Mattia Altini, Ugo De Giorgi, Andrea Rocca, Sara Bravaccini

Subjects: Get full text

The likelihood of being helped or harmed as a patient-centred tool to assess cyclin dependent kinase 4/6 inhibitors clinical impact and safety in metastatic breast cancer: a system... by Luca Mastrantoni, Armando Orlandi, Antonella Palazzo, Giovanna Garufi, Alessandra Fabi, Gennaro Daniele, Diana Giannarelli, Giampaolo Tortora, Emilio Bria

Subjects: Get full text

Relationship between Medication-Related Osteonecrosis of the Jaw and CDK4/6 Inhibitors in Breast Cancer by Loreto Domínguez Senín, David Morales Pancorbo, María Yeray Rodríguez Garcés, María Dolores Santos-Rubio, Juan Bayo Calero

Subjects: Get full text

Cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i): Mechanisms of resistance and where to find them by L. Foffano, L. Cucciniello, E. Nicolò, I. Migliaccio, C. Noto, C. Reduzzi, L. Malorni, M. Cristofanilli, L. Gerratana, F. Puglisi

Subjects: Get full text

A meta-analysis and systematic review of different cyclin-dependent kinase 4/6 inhibitors in breast cancer by Jialin Zhang, Xinyu Xu, Yeyue Zhou, Jingyang Su, Jue Wang

Subjects: Get full text